Literature DB >> 32985015

Efficacy of BRAF-Inhibitor Therapy in BRAFV600E -Mutated Adult Langerhans Cell Histiocytosis.

Antonious Z Hazim1, Gordon J Ruan1, Aishwarya Ravindran2, Jithma P Abeykoon3, Caleb Scheckel3, Robert Vassallo4, Jay H Ryu4, W Oliver Tobin5, Matthew J Koster6, N Nora Bennani3, Karen L Rech2, Jason R Young7, Mithun V Shah3, Gaurav Goyal8,9, Ronald S Go3.   

Abstract

Langerhans cell histiocytosis (LCH) is a rare histiocytic neoplasm. To date, there is a lack of U.S. Food and Drug Administration-approved treatments in adult LCH to establish optimal first-line therapy. We conducted a retrospective, single-center case series evaluating the use of BRAF inhibitors in adult patients with BRAFV600E - LCH proven by biopsy. Our case series is the first to report the use of BRAF inhibitors as first-line therapy in adults with LCH. We also report the efficacy with single-agent dabrafenib in adult LCH. All but one of our patients had favorable response to targeted therapy. © AlphaMed Press 2020.

Entities:  

Keywords:  Dabrafenib; Histiocytosis; Targeted therapy; Vemurafenib

Year:  2020        PMID： 32985015      PMCID： PMC7938396          DOI： 10.1002/onco.13541

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  11 in total

1.  Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study).

Authors:  Fleur Cohen Aubart; Jean-François Emile; Fabrice Carrat; Frédéric Charlotte; Neila Benameur; Jean Donadieu; Philippe Maksud; Ahmed Idbaih; Stéphane Barete; Khê Hoang-Xuan; Zahir Amoura; Julien Haroche
Journal:  Blood       Date:  2017-06-30       Impact factor: 22.113

2.  Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition.

Authors:  Gil Awada; Teofila Seremet; Karel Fostier; Hendrik Everaert; Bart Neyns
Journal:  Blood Adv       Date:  2018-08-28

3.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Authors:  Axel Hauschild; Jean-Jacques Grob; Lev V Demidov; Thomas Jouary; Ralf Gutzmer; Michael Millward; Piotr Rutkowski; Christian U Blank; Wilson H Miller; Eckhart Kaempgen; Salvador Martín-Algarra; Boguslawa Karaszewska; Cornelia Mauch; Vanna Chiarion-Sileni; Anne-Marie Martin; Suzanne Swann; Patricia Haney; Beloo Mirakhur; Mary E Guckert; Vicki Goodman; Paul B Chapman
Journal:  Lancet       Date:  2012-06-25       Impact factor: 79.321

4.  Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

Authors:  Grant A McArthur; Paul B Chapman; Caroline Robert; James Larkin; John B Haanen; Reinhard Dummer; Antoni Ribas; David Hogg; Omid Hamid; Paolo A Ascierto; Claus Garbe; Alessandro Testori; Michele Maio; Paul Lorigan; Celeste Lebbé; Thomas Jouary; Dirk Schadendorf; Stephen J O'Day; John M Kirkwood; Alexander M Eggermont; Brigitte Dréno; Jeffrey A Sosman; Keith T Flaherty; Ming Yin; Ivor Caro; Suzanne Cheng; Kerstin Trunzer; Axel Hauschild
Journal:  Lancet Oncol       Date:  2014-02-07       Impact factor: 41.316

5.  Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.

Authors:  Julie Charles; Jean-Claude Beani; Giacomo Fiandrino; Benoit Busser
Journal:  J Am Acad Dermatol       Date:  2014-09       Impact factor: 11.527

Review 6.  Langerhans cell histiocytosis.

Authors:  Carlos Rodriguez-Galindo; Carl E Allen
Journal:  Blood       Date:  2020-04-16       Impact factor: 22.113

7.  Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor.

Authors:  Letizia Gandolfi; Sarah Adamo; Alessandro Pileri; Alessandro Broccoli; Lisa Argnani; Pier Luigi Zinzani
Journal:  J Natl Compr Canc Netw       Date:  2015-06       Impact factor: 11.908

8.  Adult Langerhans cell histiocytosis and sclerosing cholangitis: a case report and review of the literature.

Authors:  Ibrahim Hatemi; Birol Baysal; Hakan Senturk; Kemal Behzatoglu; Erol Rustu Bozkurt; Gulsen Ozbay
Journal:  Hepatol Int       Date:  2010-08-04       Impact factor: 6.047

9.  Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.

Authors:  Eli L Diamond; Vivek Subbiah; A Craig Lockhart; Jean-Yves Blay; Igor Puzanov; Ian Chau; Noopur S Raje; Jurgen Wolf; Joseph P Erinjeri; Jean Torrisi; Mario Lacouture; Elena Elez; Ferran Martínez-Valle; Benjamin Durham; Maria E Arcila; Gary Ulaner; Omar Abdel-Wahab; Bethany Pitcher; Martina Makrutzki; Todd Riehl; José Baselga; David M Hyman
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777

10.  Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease.

Authors:  Gaurav Goyal; Mithun V Shah; Timothy G Call; Mark R Litzow; William J Hogan; Ronald S Go
Journal:  JAMA Oncol       Date:  2017-09-01       Impact factor: 31.777
View more
  3 in total

Review 1.  Adult Langerhans Cell Histiocytosis and the Skeleton.

Authors:  Danae Georgakopoulou; Athanasios D Anastasilakis; Polyzois Makras
Journal:  J Clin Med       Date:  2022-02-09       Impact factor: 4.241

2.  Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis.

Authors:  Gaurav Goyal; Jithma P Abeykoon; Marie Hu; Jason R Young; Mithun V Shah; N Nora Bennani; Timothy G Call; C Christopher Hook; Animesh Pardanani; David J Inwards; Robert Vassallo; Jay H Ryu; W Oliver Tobin; Matthew J Koster; Caroline J Davidge-Pitts; Aishwarya Ravindran; Karen L Rech; Ronald S Go
Journal:  Am J Hematol       Date:  2021-02-19       Impact factor: 10.047

3.  Experiences of a Single Center in One Hundred Ninety-Four Adult Patients With Langerhans Cell Histiocytosis.

Authors:  Claus Doberauer; Christoph Bornemann
Journal:  J Hematol       Date:  2022-08-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.